Last reviewed · How we verify
NCT03409341
Personalizing Immune Checkpoint Inhibitor Therapy
trial testing Blood and tumor tissue analysis, Clinical response. in Lung Cancer Stage IV. Withdrawn.
8 January 2020
Quick facts
| Lead sponsor | Holy Cross Hospital, Maryland |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 February 2019 |
| Primary completion | 8 January 2020 |
| Estimated completion | 22 September 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blood and tumor tissue analysis, Clinical response.
Conditions studied
- Lung Cancer Stage IV — all drugs for Lung Cancer Stage IV →
Sponsor
Holy Cross Hospital, Maryland
Who can join
Adults 18 to 70, any sex, with Lung Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03409341
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Stage IV
Currently open trials in the same condition.
- NCT06076005 — Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor · recruiting
- NCT03728361 — Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroend · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03409341 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Holy Cross Hospital, Maryland
- Last refreshed: 24 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03409341.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing